Finally, we constructed a subcutaneous xenograft model in vivo to evaluate the potential of hfCas13d‐mediated PLK1 knockdown delivered by lentiviral vectors as a therapeutic strategy for osteosarcoma. This evidence concerns the gene PLK1 and osteosarcoma.